Ultragenyx Pharmaceutical Inc.

RARE | NASDAQ

Price Alert Chart Builder DCF Calculator

$16.10

-$0.68 (-4.05%)

At close: Oct 30, 2026, 4:00 PM ET

$16.04

-$0.06 (-0.34%)

Pre-market: Nov 2, 2026, 4:20 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-4.05%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

47.7

+0.5 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #334/1028 (Top 32%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.59B

1D Range

15.92 16.93

52W Range

12.88 36.54

Valuation (TTM)

PE -2.76

PB -5.45

EV/EBITDA -5.28

Valuation (NTM)

Forward PE 84.71

Forward PEG 0.15

Price Target $25.46

Cash Flow

FCF Yield -30.8%

SBC Adj. FCF Yield -39.5%

SBC Impact -28.2%

Margins

Gross Margin 83.1%

Operating Margin -73.8%

FCF Margin -68.3%

Growth (CAGR)

Revenue 3Y | 5Y 21.2% | 14.8%

Dil EPS 3Y | 5Y 11.7% | 10.6%

FCF 3Y | 5Y 0.3% | 0.5%

Returns

ROA -46.4%

ROE 392.4%

ROIC -53.5%

Financial Health

Net Debt

$910M

Current Ratio 1.73

Interest Coverage -6.95

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations sp...

Sector Healthcare

Industry Biotechnology

Employees 1,371

IPO Date Jan 31, 2014

Website www.ultragenyx.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · globenewswire.com

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m.

5 days ago · prnewswire.com

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS Further Highlight Amgen's Broad Portfolio and Commitment to People Living with Rare Diseases THOUSAND OAKS, Calif., Oct. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026.

5 days ago · zacks.com

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

18 days ago · zacks.com

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

19 days ago · zacks.com

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

19 days ago · globenewswire.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

25 days ago · zacks.com

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

26 days ago · proactiveinvestors.com

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded to Ultragenyx after the US Food and Drug Administration approved GENGLYCOS, also known as DTX401, for glycogen storage disease (GSD) type Ia.

26 days ago · globenewswire.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).